[{"orgOrder":0,"company":"NCK AS","sponsor":"CNS Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Berubicin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"NCK AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NCK AS \/ NCK A\/S.","highestDevelopmentStatusID":"8","companyTruncated":"NCK AS \/ NCK A\/S."}]

Find Clinical Drug Pipeline Developments & Deals by NCK AS

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : For the large scale production of Berubicin, its lead drug candidate for the treatment of glioma brain tumors.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 14, 2020

                          Lead Product(s) : Berubicin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : CNS Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank